ADULT
ADULT
SKIN & SOFT TISSUE INFECTIONS
In this topic:
The key principle in managing purulent infection should be incision and drainage.
1.1 Folliculitis
Common organisms:
Staphylococcal aureus
Pseudomonas aeruginosa
Malassezia furfur
Herpes simplex virus
Demodex spp.
1.1.1 Mild
Usually self-limiting and no treatment is required.
Consider good skin hygiene.
Warm compresses for comfort.
1.1.2 Known or Suspected Staphylococcal
Preferred
Topical 2% fusidic acid q8-12h
OR
Topical 2% mupirocin q8h
(Outpatient use only)
Alternative
--
Comments
General measures include warm compress, antiseptic washes, good skin hygiene and clean sharp razors when shaving.
Obtain a pus or swab for culture and sensitivity if accessible.
Topical antibiotic therapy is preferred for folliculitis that persists with general measures and involves a limited area of the skin.
1.1.3 Deep or Extensive Lesions
Preferred
Cloxacillin 500mg PO q6h
OR
Cephalexin 1000mg PO q12h
Alternative
--
Comments
Systemic antimicrobial therapy with S. aureus coverage is suggested for patients with deep or extensive folliculitis that fails to resolve or recurs after topical therapy.
Consider the etiology of the folliculitis and the severity and the distribution of the lesions.
Referral to a dermatologist if other etiologies are considered, especially when initial systemic treatment fails:
1.Gram-negative folliculitis (e.g. Enterobacter, Klebsiella, Escherichia, Serratia, Morganella, and Proteus species): primarily in patients on long-term antibiotic therapy, most often during treatment for acne.
2. Pseudomonal folliculitis: appears 8-48 hours after exposure to contaminated water (e.g. hot tub/spa) or wet suits.
3. Folliculitis caused by Malassezia furfur, Demodex mites or herpes simplex virus: seen in immunocompromised patients.
1.2 Furuncles (“Boils”)
Preferred
Mild (Localised):
Cloxacillin 500mg PO q6h
Moderate to severe (Extensive/generalised; with or without systemic symptoms, or immunocompromised patients):
Amoxicillin/clavulanate 1.2g IV q8h
OR
Ampicillin/sulbactam 3g IV q6-8h
Alternative
Mild (Localised):
Amoxicillin/clavulanate 625mg PO q8h
Comments
Duration: 5 days
Consider warm compresses and drainage first; if these measures fail, then initiate antibiotic therapy.
For moderate to severe boils, or those presenting with systemic manifestations, manage according to the treatment protocol for carbuncles.
Consider switching from IV to PO therapy if condition improves.
1.3 Carbuncles
Common organism:
Staphylococcus aureus
Preferred
Cloxacillin 1-2g IV q6h
OR
Cefazolin 1g IV q8h
Alternative
Amoxicillin/clavulanate 1.2g IV q8h
OR
Ampicillin/sulbactam 3g IV q6h
Comments
Duration: 7-10 days
Surgical drainage is the mainstay of treatment.
Consider IV to PO switch if adequate surgical treatment and rapid clinical response.
Consider targeted therapy once culture results are available.
2.1 Localised Impetigo
Common organism:
Staphylococcus aureus
Streptococcus pyogenes
Preferred
Topical 2% fusidic acid q8-12h
OR
Topical 2% mupirocin q8h
(Outpatient use only)
Alternative
Cloxacillin 500mg PO q6h
OR
Cephalexin 500mg PO q12h
Comments
Duration: 5 days
2.2 Generalised Impetigo/Ecthyma
Preferred
Cloxacillin 500mg PO q6h
OR
Cephalexin 1000mg PO q12h
Antibiotic allergy:
Erythromycin ethylsuccinate 800mg PO q12h
Alternative
Amoxicillin/clavulanate 625mg PO q8h
Other alternative/in case of CA-MRSA:
Clindamycin 300mg PO q6h
OR
Trimethoprim/sulfamethoxazole 160/800mg PO q12h
2.3 Erysipelas
Common organism:
Streptococcus pyogenes
Preferred
Phenoxymethylpenicillin 500mg PO q6h
OR
Amoxicillin 500mg PO q8h
If severe:
Benzylpenicillin 2-4MU IV q4-6h
*CA-MRSA:
Clindamycin 300mg PO q6h
OR
Trimethoprim/sulfamethoxazole 160/800mg PO q12h
Alternative
Cephalexin 1000mg PO q12h
If severe:
Cefazolin 1g IV q8h
OR
Cefuroxime 750mg IV q8h
CA-MRSA:
**Vancomycin 15-20mg/kg q8-12h; not to exceed 2g/dose
Comments
Duration: 5 days
*CA-MRSA: IV Vancomycin is used if oral therapy is not feasible
**Refer to Appendix 1 for vancomycin loading dose.
2.4 Ecthyma gangrenosum
Most common causative organism is Pseudomonas sp., however antibiotics need to be tailored according to susceptibility result.
Preferred
Ciprofloxacin 400mg IV q12h
OR
*Piperacillin/tazobactam 4.5g IV q6 – 8h
Alternative
Ceftazidime 2g IV q8h
OR
Cefepime 2g IV q8h
Comments
Duration: 7 days (based on clinical response)
Consider IV to PO switch once patient's condition improves. Refer to Appendix 6.
*Piperacillin/tazobactam: if given as q8h, to be given as extended infusion (over 3 – 4 hours).
2.5 Cellulitis
Mild cellulitis: without systemic signs of infection. Common organisms: Streptococcus pyogenes & Staphylococcus aureus
Moderate cellulitis: with *SIRS but no hypotension. Common organisms: Streptococcus pyogenes & Staphylococcus aureus
Severe cellulitis: with *SIRS and hypotension. Common organisms:Streptococcus pyogenes & Staphylococcus aureus
*Systemic inflammatory response syndrome (SIRS):
1. fever,
2. tachypnea,
3. tachycardia
4. abnormal white cell count
Preferred
Mild:
Cloxacillin 500mg PO q6h
OR
Cephalexin 1000mg PO q12h
OR
Amoxicillin 500mg PO q8h
Moderate:
Cloxacillin 1-2g IV q6h
OR
Cefazolin 1-2g IV q8h
Severe:
*Piperacillin/tazobactam 4.5g IV q6h-8h
(Deescalate once cultures are available/ Necrotizing fasciitis ruled out)
**Antibiotic Prophylaxis:
Phenoxymethylpenicillin (Penicillin V) 250mg PO q12h (500mg PO q12h if BMI ≥ 33)
Alternative
Mild:
Amoxicillin/clavulanate 625mg PO q8h
OR
Ampicillin/sulbactam 375mg PO q12h
OR
Cefuroxime 500mg PO q12h
Moderate:
Ampicillin/sulbactam 3g IV q6h
OR
Amoxicillin/clavulanate 1.2g IV q8h
OR
Cefuroxime 750mg-1.5g IV q8h
Severe:
Ampicillin/sulbactam 3g IV q6h
OR
Amoxicillin/clavulanate 1.2g IV q8h
Antibiotic allergy:
Clindamycin 600mg IV q6h
(Deescalate once cultures are available/ Necrotizing fasciitis ruled out)
Antibiotic Prophylaxis:
Antibiotic allergy:
Clarithromycin 250mg PO q24h
OR
Erythromycin ethylsuccinate 400mg PO q12h
Comments
Duration: 5-10 days (longer duration may be required in case of no clinical improvement or if an underlying medication condition is present).
Consider IV to PO switch once patient's condition improves. Refer to Appendix 6.
Refer to Appendix 3 for antibiotic allergy.
*Piperacillin/tazobactam: if given as q8h, to be given as extended infusion (over 3 – 4 hours).
**Antibiotic prophylaxis may be considered in patients with 3 to 4 episodes of recurrent cellulitis per year despite attempts to treat or control predisposing factors such as lymphoedema, obesity, inflammatory dermatoses, tinea pedis and venous insufficiency.
Duration of antibiotic prophylaxis: 6-12 months depending on recurrence of event. Reassess the need for further prophylaxis if indicated thereafter.
2.6 Bite-Related Infections
Common organisms:
Dog/cat bite: Pasteurella multocida, Capnocytophaga canimorsus
Human bite: Eikenella corrodens, anaerobes, Staphylococcus aureus
Monkey bite: Streptococcus spp., Staphylococcus aureus, anaerobes,*Cercopithecine Herpesvirus 1 (exposed to macaques)
Rodent bite: Francisella tularensis, Leptospira spp, Pasteurella multocida, Spirillum minor
Reptile (E.g.: crocodiles, lizards, snakes, turtles) bite: Anaerobes, Enterobacterales
Consider antibiotic prophylaxis in these cases:
Human bite
Cat bite
Delayed presentation > 8 hours
Deep puncture wound extending or close to bone and joint
Crush associated injury
Immunocompromised patients
For all bite-related wounds, thorough wound irrigation and/or debridement must be of utmost priority. All injuries with broken skin require exploration and washout.
Consultation with a Plastic Surgeon should be considered for involvement of high-risk or special areas such as the face, hands, feet, and genitalia.
Role of ATT: The risk of tetanus needs to be evaluated to provide adequate post-exposure prophylaxis by vaccination. For further information on tetanus vaccine, please refer to Guidelines for Adult Immunisation.
For management of rabies, please refer to MOH Guideline on Rabies Management in Human and Animals.
Preferred
Dog/cat/human/rodent/reptile bite:
Amoxicillin/clavulanate 625mg PO q8h or 1.2g IV q8h
Monkey bite:
Amoxicillin/clavulanate 625mg PO q8h or 1.2g IV q8h
PLUS
*Acyclovir 800 mg PO 5 times daily for 14 days
Alternative
Antibiotic allergy:
Cefuroxime 750mg-1.5g IV q8h
OR
Ceftriaxone 2g IV q24h
PLUS
Metronidazole 500mg IV q8h
Oral Option:
Doxycycline 200mg PO q24h on Day 1 followed by 100mg-200mg PO q24h
OR
Cefuroxime 500mg PO q12h
PLUS
Metronidazole 400mg PO q8h
Comments
Duration:
Prophylaxis: 3 days
Treatment: 5 days
*Add acyclovir only when exposed to a macaque via bites and scratches, exposure to tissue culture material, exposure to tissue obtained during autopsies of monkeys, needlestick injuries, cage scratches, mucosal splash.
2.7 Cat Scratch Disease
Common organisms:
Bartonella henselae
Preferred
Azithromycin 500mg PO on Day 1, then 250mg PO q24h for 4 days
Alternative
--
Comments
--
2.8 Sea Water Exposure
Common organisms:
Vibrio sp.
Preferred
Doxycycline 200mg STAT, then 100mg PO q12h
MAY ADD
*Ceftriaxone 2g IV q24h
Alternative
--
Comments
*Consider adding third generation cephalosporins in severe infections.
2.9 Fresh or Brackish Water Exposure
Common organisms:
Aeromonas sp.
Plesiomonas
Staphylococcus aureus
Streptococcus pyogenes
Preferred
Trimethoprim/sulfamethoxazole 320/1600mg PO q12h
Alternative
Ciprofloxacin 400mg IV q12h
OR
Ciprofloxacin 750mg PO q12h
PLUS
Cloxacillin 500mg PO q6h
MAY ADD
*Metronidazole 400mg PO q8h
Comments
Oral therapy is encouraged if wounds are not associated with systemic features or involving deeper tissues.
Add metronidazole if wounds immersed in soil- or sewage-contaminated water.
2.10 Neutropenic Patients
Common organisms:
Pseudomonas aeruginosa
Other Gram-negatives
Preferred
*Piperacillin/tazobactam 4.5g IV q6-8h
OR
Cefepime 2g IV q8h
Alternative
--
Comments
*Piperacillin/tazobactam: if given as q8h, to be given as extended infusion (over 3 – 4 hours).
2.11 Methicillin Resistance Staphylococcus aureus (MRSA) Skin & Soft Tissue Infection
Preferred
Vancomycin 15-20mg/kg IV q8-12h
In severe infections:
To load with vancomycin 25-30mg/kg IV, followed by 15-20mg/kg (actual body weight) IV q8-12h; not exceeding 2g/dose
Alternative
Linezolid 600mg IV/PO q12h
Depending on culture and susceptibility testing, can consider the following options:
Clindamycin 300-600mg IV/PO q6-8h
OR
Trimethoprim/sulfamethoxazole 160/800mg PO q12h
OR
Doxycyline 100mg PO q12h
Comments
Consider IV to PO switch if condition improves. Refer to Appendix 6 for IV to PO switch.
Refer to Appendix 1 for vancomycin loading dose.
MRSA Decolonisation strategy:
Use mupirocin 2% for nasal application bilateral nostrils.
Use chlorhexidine 4% bath or 2% wipe for body application (especially for high carriage sites such as axilla, groin and perineal region).
Consider CA-MRSA if:
Outbreaks of known CA-MRSA
Non-resolving cellulitis
Common organisms:
Staphylococcus aureus
Coagulase negative Staphylococcus
Gram-negative organisms
Grade 1:
Observe cannula
Grade 2:
Resite/Remove the intravenous cannula
Grade 3-4:
Remove the intravenous cannula and take blood culture;
Consider treatment
Grade 5:
Take blood culture
Resite/remove cannula
Initiate treatment
Preferred
Grade 3-5:
Empirical treatment:
Cloxacillin 1g IV q6h
If blood culture negative and clinical improvement, to switch to oral:
Cloxacillin 500mg PO q6h
OR
Cephalexin 1000mg PO q12h
Alternative
Grade 3-5:
Cefazolin 2g IV q8h
Comments
Duration: 5 days (depending on clinical response)
Peripheral intravenous catheters with associated pain, induration, erythema, or exudate should be removed.
VISUAL INFUSION PHLEBITIS SCORE
Score 0:
Insertion site healthy, no signs of phlebitis
Score 1:
Presence of one of the following signs: Slight pain or slight redness at IV insertion site.
Score 2:
Presence of 2 of the following signs:
Pain at IV site, redness or swelling.
Score 3:
Presence of all of the following signs:
Pain along the path of the cannula, redness around the insertion site and swelling.
Score 4:
Presence of all of the following signs:
Pain along the path of the cannula, redness around the insertion site, swelling, palpable venous cord.
Score 5:
Presence of all of the following signs:
Pain along the path of the cannula, redness around the insertion site, swelling, palpable venous cord, febrile.
Common organisms:
Polymicrobial organism
The mainstay of management is prevention.
Preferred
Management depends on local assessment and grading of the pressure injury, using the National Pressure Injury Advisory Panel (NPIAP) Pressure Injury Stages.
To consider antibiotic if presence of systemic infection:
Ampicillin/sulbactam 3g IV q6h
OR
Amoxicillin/clavulanate 1.2g IV q8h
Alternative
--
Comments
To consider other sources of infection and escalate antibiotics accordingly.
May consider oral antibiotics in localised infection.
Consider IV to PO switch if condition improves. Refer to Appendix 6 for IV to PO switch.
5.1 Hansen’s Disease (Leprosy)
Mycobacterium Leprae
Preferred
Rifampicin 600mg PO once a month (supervised)
PLUS
Dapsone 100mg PO q24h
PLUS
Clofazimine 300mg PO once a month and 50mg PO q24h
Duration:
Paucibacillary: 6 months
Multibacillary: 1 year
Alternative
*Bacterial resistance or hypersensitivity to first line:
Can be substituted with one of the following:
Ofloxacin 400mg PO q24h
OR
Minocycline 100mg PO q24h
OR
Clarithromycin 500mg PO q24h
Comments
*Second line or drug-resistant regimen can only be initiated by a dermatologist.
Prophylaxis of leprosy with single dose rifampicin for contacts of leprosy patients after excluding leprosy and TB disease, and in the absence of other contraindication:
10-14 years old: 450 mg
≥15 years old: 600 mg
5.2 Non-tuberculous Mycobacterial (NTM) Skin and Soft Tissue Infections
Treatment depends on the patient’s individual susceptibility and the site of infection. It often involves combination therapy with two to three antimicrobial agents for a prolonged period of time (often 6 months to a year).
NTM are intrinsically resistant to many antibiotics. Antibiotic susceptibility testing can be performed at appropriate reference laboratories. Selection of antibiotics are often empirically chosen based on guideline.
5.2.1 Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium fortuitum/chelonae/abscessus complex
Preferred
Clarithromycin 500mg PO q12h
OR
Azithromycin 500mg PO q24h
PLUS
Rifampicin 600mg PO q24h
OR
Ethambutol 25mg/kg PO q24h
OR
Doxycycline 100mg PO q12h
Alternative
Amikacin 15mg/kg IV q24h
Comments
Duration: 6-12 months or until clinical resolution
5.2.3 Mycobacterium ulcerans (Buruli ulcer)
Preferred
Rifampicin 10mg/kg PO q24h
PLUS
Clarithromycin 7.5mg/kg PO q12h
Alternative
Rifampicin 10mg/kg PO q24h
PLUS
Streptomycin 15mg/kg IM q24h for 4 weeks
Followed by:
Rifampicin 10mg/kg PO q24h
PLUS
Clarithromycin 7.5mg/kg PO q12h
Comments
Wide surgical excision and debridement are important.
Duration
WHO category 1:
Pre-ulcerative lesions and skin lesions smaller than 5 cm, duration of antibiotic 4 weeks with simple excision or 8 weeks of antibiotic therapy only
WHO category 2:
Antibiotic at least 8 weeks with supportive care (E.g.: surgery)
WHO category 3:
Lesions > 15cm, antibiotic plus surgical debridement and reconstruction. Duration of treatment depends on clinical response as complications are common (joint and bone involvement)
6.1 Tinea capitis
Common organism:
Trichophyton
Microsporum
Preferred
Griseofulvin 500mg PO q12h for 6 to 12 weeks or longer until fungal cultures are negative
OR
Terbinafine 250mg PO q24h
PLUS
2.5% selenium sulphide shampoo
OR
2% ketoconazole shampoo,
2 – 3 times per week for 2 weeks
Alternative
*Itraconazole 5mg/kg PO q24h
OR
Fluconazole 6mg/kg PO q24h
Duration is based on mycological result/ type of treatment agent and clinical response. E.g.:
Trichophyton sp : 2-4 weeks
Microsporum sp : 8-12 weeks
Comments
Other recommendations:
For kerion, griseofulvin should be considered as first line unless Tricophyton has been cultured as the pathogen. Duration of treatment may be longer.
Contacts of patient may be treated with 2% ketoconazole shampoo 2 – 3 times per week for 2 weeks.
Surgical excision is to be avoided.
Topical therapy alone is not recommended for the management of tinea capitis.
Consider adding oral prednisolone in selected cases.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or oranges drinks). Avoid PPIs and H2 blockers.
6.2 Tinea barbae
Same as treatment of tinea capitis
6.3 Tinea corporis/Tinea cruris/Tinea faciei
Common organism:
Trichophyton
Microsporum
Epidermophyton
Preferred
Mild infections:
Topical imidazoles or allylamines cream/lotion. E.g.:
Clotrimazole 1% LA q12h
OR
Miconazole 2% LA q12h
OR
Ketoconazole 2% shampoo LA q12h
OR
Terbinafine 1% LA q12h
Duration: Until clinical clearance with additional 2 weeks.
Extensive infections:
Terbinafine 250mg PO q24h for 2 weeks
OR
*Itraconazole 200mg PO q24h for 2 weeks
OR
Griseofulvin 500mg PO q12h or q24h for 4-6 weeks
Alternative
Extensive Infections:
Fluconazole 100mg PO daily for 1-2 weeks
OR
Fluconazole 200mg PO once weekly for 3-4 weeks
Comments
Other recommendations:
In patients with renal or hepatic impairment, caution should be exercised while prescribing systemic antifungals.
Terbinafine clearance is significantly reduced in patient with renal impairment. Other systemic antifungals are preferred in these patients.
Topical nystatin should not be used in dermatophytosis as they are not effective against dermatophytes.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
Antifungal therapy should be adjusted based on culture results and susceptibility findings.
6.4 Tinea manuum/ Tinea pedis
Common organism:
Trichophyton
Microsporum
Epidermophyton
Preferred
First line:
Topical antifungals as mentioned in tinea corporis for 4-8 weeks
Resistant cases:
Terbinafine 250mg PO q24h for 2-4 weeks
OR
*Itraconazole 200mg PO q24h for 2-4 weeks
OR
Griseofulvin 500mg PO q12h for 6-12 weeks
Alternative
Resistant cases:
Fluconazole 150mg/week PO for 4 weeks
Comments
Other recommendations:
● Topical keratolytic agents can be used in conjunction with antifungals for hyperkeratotic type of tinea pedis/manuum.
● Potassium permanganate in 1:10,000 dilution wet dressings, applied for 20 min 2–3 times/day, may be helpful if vesiculation or maceration is present.
● Systemic antifungals can be prescribed as first line treatment in severe moccasin-type tinea pedis or severe recurrent tinea with blisters.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
6.5 Tinea unguium (onychomycosis)
Common organism:
Trichophyton
Microsporum
Epidermophyton
Preferred
*Amorolfine 5% Nail Lacquer once weekly application
Duration:
Fingernails: 6 months
Toenails: 12 months
OR
**Pulse itraconazole 200mg PO q12h for 1 week per month
Duration:
Fingernails: 2 months
Toenails: 3 months
OR
Terbinafine 250mg PO q24h
Duration:
Fingernails: 6 weeks
Toenails: 12 weeks
Alternative
Griseofulvin 500mg PO q12h
Duration:
Fingernails: 6 months
Toenails: 12 months
OR
Fluconazole 150mg PO once weekly
Duration:
Fingernails: ≥ 3 months
Toenails: 6-12 months
Comments
*Amorolfine 5% Nail Lacquer is not indicated for children less than 12 years old.
Patients with contraindications to systemic agents may consider topical antifungal agents.
Diagnosis of onychomycosis should be confirmed with a KOH preparation test, culture, or PAS Stain. Empirical treatment is not recommended.
**Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
6.6 Tinea versicolor
Common organism:
Malassezia furfur
Pityrosporum orbiculare
Preferred
First line: Topical treatment only
Selenium sulphide 2% shampoo;
Apply to affected areas 10 minutes before bathing, or
Dilute to 1:1 with water, apply and leave overnight (treat for 1-2 weeks)
OR
Ketoconazole 2% shampoo, apply to affected areas 10 minutes before bathing
For face:
Topical imidazole for 4-6 weeks. E.g.: Miconazole 2% cream, clotrimazole 1% cream LA q12h
For recurrent or resistant cases:
*Itraconazole 200mg PO q24h for 1 week or 400mg single dose
OR
Fluconazole 300mg PO weekly dose for 2 weeks
Alternative
Alternative for selenium sulphide and ketoconazole shampoo:
Sulfur preparation
OR
Salicylic solution
Comments
Recommendations:
Ketoconazole shampoo or selenium sulphide shampoo can be used once every two to four weeks for approximately six months in order to try and prevent recurrence.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (e.g.: Cola or orange drinks). Avoid PPIs and H2 blockers.
6.7 Candidiasis
Common organism:
Candida albicans
Preferred
Mild cutaneous candidiasis:
Topical imidazole q12h until clear. E.g.:
Miconazole 2% cream
OR
Clotrimazole 1% cream
Extensive cutaneous candidiasis:
*Itraconazole 200mg PO q24h for 1 week
Alternative
Extensive cutaneous candidiasis:
Fluconazole 100mg PO q24h for 1 week (in severe and immunocompromised patients)
Comments
Treatment of sexual partner is advisable in case of recurrent infection.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
6.8 Subcutaneous Fungal Infections
Lymphocutaneous and Cutaneous Sporotrichosis / Chromoblastomycosis
Preferred
*Itraconazole 200mg PO q12h until all lesions have resolved
(usually for a total of 3–6 months)
Alternative
For patients not able to tolerate itraconazole:
Terbinafine 500mg PO q12h
OR
Fluconazole 400mg q24h
Comments
In some immunocompromised condition such as AIDS, longer treatment may be necessary. Refer to Infections in Immunocompromised Patients - Opportunistic Infections in HIV Patients section.
*Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
**Avoid azole in pregnancy
6.9 Systemic sporotrichosis
(pulmonary, osteoarticular, meningeal, or disseminated sporotrichosis)
Preferred
Amphotericin B deoxycholate 0.7-1mg/kg IV q24h for 2 weeks
OR
*Amphotericin B (lipid formulation) 3–5mg/kg q24h for 2 weeks
Followed by;
**Itraconazole 200mg PO q12-24h for at least of 12 months duration
***In pregnancy and breastfeeding:
Terbinafine 500mg PO q12h
Alternative
**In pregnancy and breastfeeding:
Amphotericin B deoxycholate 0.7-1mg/kg IV q24h for 2 weeks
OR
*Amphotericin B (lipid formulation) 3–5mg/kg q24h for 2 weeks
Comments
In some immunocompromised condition such as AIDS, longer treatment may be necessary. Refer to Infections in Immunocompromised Patients - Opportunistic Infections in HIV Patients section.
*Not listed in MOH Drug Formulary.
**Itraconazole: Absorption depends on gut acidity. Take capsule with food and acidic beverage (E.g.: cola or orange drinks). Avoid PPIs and H2 blockers.
***Avoid azole in pregnancy.
6.10 Cutaneous fungal infection in immunocompromised patients
Refer to treatment of disseminated fungal infection in Infections in Immunocompromised Patients - Opportunistic Infections in HIV patients section.
Skin biopsy for histopathological examination (HPE) and culture are advised before commencing treatment.
6.11 Aspergillus sp, Scedosporium apiospermum, Lomentospora prolificans and Fusarium sp infection
Preferred
Voriconazole 6mg/kg IV q12h for 2 doses,
followed by 4mg/kg IV q12h
Alternative
Amphotericin B (deoxycholate) 0.7–1mg/kg q24h
OR
*Amphotericin B (lipid formulation) 3–5mg/kg q24h
Comments
For Lomentospora prolificans, consider surgical debridement and reduction of immunosuppression.
Consider IV to PO switch once clinically improving and can tolerate orally.
*Not listed in MOH Drug Formulary.
6.12 Cryptococcal skin infections
Preferred
Fluconazole 400mg PO q24 h
Alternative
--
Comments
--
6.13 Peniciliosis, disseminated Histoplasmosis and disseminated Cryptococcosis
Refer to treatment of disseminated fungal infection in Infections in Immunocompromised Patients - Opportunistic Infections in HIV patients section.
7.1 Herpes Simplex Infections
7.1.1 Non-genitalia
Preferred
Acyclovir 400mg PO q8h
Alternative
*Valacyclovir 1g PO q12h
OR
*Famciclovir 500mg PO q12-24h
Comments
Duration: 7 days
Vesiculation for trunk and limbs:
Potassium permanganate in 1:10,000 dilution wet dressings, applied for 20 min 2–3 times/day, may be helpful.
Vesiculation for head and neck:
Normal saline wet dressings, applied for 20 min 2–3 times/day, may be helpful.
*Not listed in MOH Drug Formulary.
7.1.2 Genitalia
Refer to Sexually Transmitted Infections section.
7.2 Varicella zoster (Chickenpox)
Preferred
Immunocompetent:
Acyclovir 800mg PO 5 times daily for 7 days
Immunocompromised:
Acyclovir 10mg/kg IV q8h for 7 days (change to oral once there is an improvement)
Alternative
--
Comments
Advisable to start treatment early within 48 hours.
Vesiculation for trunk and limbs:
Potassium permanganate in 1:10,000 dilution wet dressings, applied for 20 min 2–3 times/day, may be helpful.
Vesiculation for head and neck:
Normal saline wet dressings, applied for 20 min 2–3 times/day, may be helpful.
7.3 Herpes zoster
Preferred
Refer to varicella zoster treatment.
Alternative
--
Comments
Topical antiviral treatment is not recommended for herpes zoster.
Vesiculation for trunk and limbs:
Potassium permanganate in 1:10,000 dilution wet dressings, applied for 20 min 2–3 times/day, may be helpful.
Vesiculation for head and neck:
Normal saline wet dressings, applied for 20 min 2–3 times/day, may be helpful.
Systemic antiviral treatment is recommended for all immunocompromised patients or for immunocompetent patients with the following criteria:
1. >50 years of age
2. Moderate or severe pain
3. Moderate or severe rash
4. Non-truncal involvement
Advisable to start treatment early within 48-72 hours.
8.1 Scabies
Common organism:
Sarcoptes scabiei
Preferred
Apply benzyl benzoate emulsion 25% (EBB) from neck down and leave for 24 hours for 2-3 days
OR
Apply permethrin 5% lotion/cream and leave for 8 hours
Repeat application after 1 week.
In pregnancy/Immunocompromised:
Apply permethrin 5% lotion/cream and leave for 8 hours.
Repeat application after 1 week.
Alternative
--
Comments
Clothing and bedding of persons with scabies should be washed in hot water and dried.
8.2 Head Lice
Common organism:
Pediculus humanus capitis
Preferred
Apply permethrin 1% lotion to scalp for 10 minutes and wash off
OR
Apply malathion 1% shampoo and leave for 15 minutes and wash off
Repeat application after 1 week.
Alternative
--
Comments
Use special fine-toothed nit comb to reduce risk of re-infestation.
8.3 Body Lice/Pubic Lice
Common organism:
Pediculus humanus
Preferred
Apply malathion lotion 0.5% for 8-12 hours and wash off
OR
Apply permethrin 1% cream to affected area for 10 minutes and wash off
Alternative
--
Comments
--
9.1 Breast Infections
9.1.1 Breast Abscess/Mastitis
Common organism:
Staphylococcus aureus
Preferred
Cloxacillin 1-2g IV q6h
OR
Cefazolin 1-2g IV q8h
Alternative
Amoxicillin/clavulanate 625mg PO q8h
OR
Ampicillin/sulbactam 750mg PO q12h
Antibiotic allergy:
Clindamycin 600mg IV/PO q8h
Comments
Surgical drainage is the mainstay of management.
Duration: 10 to 14 days but shorter antibiotic duration (5 to 7 days) can be considered if adequate source control and local wound management has shown clinical improvement.
Refer to Appendix 3 for antibiotic allergy.
9.1.2 Other Complicated Breast Infections
(E.g.: foreign body-related infections)
Empirical antibiotics are not recommended.
Early referral to primary/plastic surgery for input.
9.2 Burn-Related Infections
Burn wound is considered sterile up to 48 hours.
Not all burn injuries require antibiotics.
Ideal care is in a dedicated burn unit.
Consider plastic surgery input.
Consider antibiotic prophylaxis for patients with severe burn and high-risk group
9.2.1 Severe Burn and High-risk Group
Preferred
Cefazolin 1-2g IV q8h
Alternative
Amoxicillin/clavulanate 1.2g IV q8h
OR
Ampicillin/sulbactam 3g IV q6-8h
Comments
Antibiotics may be necessary in certain high-risk groups:
Inhalation injury
Immunocompromised patients (E.g.: extreme age groups (elderly and children), diabetes mellitus, obesity, impaired immunity)
Delay in burn wound excision
Mechanical ventilation
Total body surface area (TBSA) burn > 20%
9.3 Orofacial-Related Infections
9.3.1 Odontogenic Infections
Refer to Oral/Dental Infections section
9.3.2 Non-odontogenic Infections
Pyogenic infections of the face and neck. E.g.: facial cellulitis/abscess
Preferred
Amoxicillin/clavulanate 1.2g IV q8h
Alternative
Antibiotic allergy:
Clindamycin 600mg IV/PO q8h
Comments
Surgical drainage +/- debridement is the mainstay of therapy.
Refer to Otorhinolaryngology Infections section for deep neck space abscess.
9.3.3 Musculoskeletal Infections
Cartilage infections - pinna (external ear/auricle) and nose
Preferred
Amoxicillin/clavulanate 1.2g IV q8h
Alternative
Ampicillin/sulbactam 3g IV q6-8h
For cartilage penetration:
Ciprofloxacin 400mg IV BD
OR
Ciprofloxacin 500mg PO BD
Comments
References:
Stevens et al. Clinical Infectious Diseases 2014;59(2)
Luelmo-Aguilar J, Santandreu MS. Folliculitis: recognition and management. Am J Clin Dermatol. 2004;5(5):301-10.
Lousada MB, Lachnit T, Edelkamp J et al. Exploring the human hair follicle microbiome. Br J Dermatol. 2021;184(5):802-815.
NICE Guidelines {NG153] 2020: Impetigo: antimicrobial prescribing
Guidelines on the Management of Cellulitis in Lymphoedema. British Lymphology Society and the Lymphoedema Support Network 2022.
Sarkar S et al. Indian Dermatol Online J 2016;7:36.
Reich HL et.al. J Am Acad Dermatol. 2004;50
Morton N Swartz. N Engl J Med 2004;350:904-12.
CREST guidelines. 2005
Begier EM et al. Clin Infect Dis 2004;39:1446.
Jeffrey I. Cohen et al. Clinical Infectious Diseases, 2002;35(10):1191–1203.
Australian Therapeutic Guidelines: Bite Wound Infection, including clenched fist injury 2023.
Management of water-immersed wound infections in children, Children's Health Queensland Hospital and Health Service 2023
Jackson A. Nurs Times. 1998; 94(4):68, 71.
WHO Guidelines for the diagnosis, treatment and prevention of leprosy 2018
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) 2017
WHO Buruli ulcer (Mycobacterium ulcerans infection) 2020 (https://www.who.int/news-room/fact-sheets/detail/buruli-ulcer-(mycobacterium-ulcerans-infection))
Bhambri S, Bhambri A, Del Rosso JQ. Dermatol Clin. 2009;27(1):63-73.
Chung, J., Ince, D., Ford, B.A. et al. Am J Clin Dermatol 2018;19(6):867–878.
Primary Care Dermatology Society UK 2013
L.C. Fuller, R.C. Barton, M.F. Mohd Mustapa, L.E. Proudfoot, S.P. Punjabi and E.M. Higgins, British Association of Dermatologists’ guidelines for the management of tinea capitis 2014
RxFiles Newsletter : Antifungal newsletter (April 2010) Canadian : Bugs and Drugs
Alok Kumar Sahoo et al, indian journal of dermatology 2016, Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review
Craig G Burkhart et al. Tinea Versicolor Treatment & Management.medscape. updated Dec 2013
Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America
Centers for Disease Control and Prevention (CDC) 2010
IDSA Guidelines for Intravascular Catheter-Related Infection • CID 2009:49
ESPID Reports and Review: The Pediatric Infectious Disease Journal 2014
Rook Textbook Dermatology 4th edition (www.dermnetnz.org)
Cernik C, et al. The treatment of herpes simplex infections : An evidence-based review. Arch Internal Med. 2008;168(11):1137-1144.
WHO AWaRe Antibiotic Book 2022.
Then Sanford Guide to Antimicrobial Therapy 2022
Johns Hopkins Antimicrobial Guidelines 2013-14
CDC Guidelines for the treatment of head lice 2019.
Uptodate - Burn wound infection and sepsis (accessed 30 Oct 2023)
Australian Therapeutics Guideline: Lactational Mastitis (accessed 30 Oct 2023)
The Royal Women's Hospital Guideline: Infant Feeding - Mastitis and Breast Abscess (published 29/7/2020, accessed on 30th Oct 2023)
Ramos G, Cornistein W, Cerino GT, Nacif G. Systemic antimicrobial prophylaxis in burn patients: systematic review. J Hosp Infect. 2017;97(2):105-114.
Pappas PG, Kauffman CA, Andes DR et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.
Australian Therapeutics Guideline: Acute odontogenic infection (accessed 30 Oct 2023)
Infectious Disease Society of America (IDSA): Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by IDSA.(last updated August 16, 2018, accessed Sept 4, 2025). Accessed via URL: https://www.idsociety.org/practice-guideline/skin-and-soft-tissue-infections/
NHS Tayside. Recurrent Cellulitis/Erysipelas: Points to consider before prescribing prophylaxis for Adult Patients. (updated April 2023, accessed Sept 4, 2025) accessed via URL: https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs/Cellulitis%20prophylaxis%20flowchart.pdf
Malaysian Society of Infectious Diseases & Chemotherapy. Guidelines for Adult Immunization 3rd edition: Tetanus. (revised Nov 2024, accessed Sept 4, 2025) acessed via URL: https://adultimmunisation.msidc.my/tetanus/)
National Institute for Health and Care Excellence (NICE) Guideline. Human and animal bites: antimicrobial prescribing. (published Nov 4, 2020, accessed on Sept 4, 2025) accessed via URL: https://www.nice.org.uk/guidance/ng184
Chen W, Li S. Effects of daily bathing with chlorhexidine and acquired infection of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: a meta-analysis. J Thorac Dis 2013;5(4):518-524. doi: 10.3978/j.issn.2072-1439.2013.08.30. (accepted for publication Aug 16, 2013, accessed Sept 4, 2025)
National Pressure Injury Advisory Panel (NPIAP). NPIAP Pressure Injury Stages. Accessed Sept 4, 2025. Accessed via URL: https://cdn.ymaws.com/npiap.com/resource/resmgr/online_store/npiap_pressure_injury_stages.pdf
Manual Pengurusan Kusta Kebangsaan edisi 3. (updated 2023, accessed Sept 4, 2025). Accessed via URL: https://infosihat.moh.gov.my/images/media_sihat/garis_panduan/pdf/Manual%20Pengurusan%20Kusta%20Kebangsaan.pdf
Mycobacterium Marinarum. John Hopkins Guides. Accessed Sept 4, 2025
USA Center for Disease Control and Prevention (CDC). Clinical Overview of Nontuberculous Mycobacteria (NTM) (published April 15, 2024, accessed on Sept 4, 2025) accessed via URL: https://www.cdc.gov/nontuberculous-mycobacteria/hcp/clinical-overview/index.html)
USA Center for Disease Control and Prevention (CDC).Clinical Care of Scabies. (updated Dec 18, 2023, accessed Sept 4, 2025) accessed via URL: https://www.cdc.gov/scabies/hcp/clinical-care/index.html